As Advair Sales Fall, GSK’s Witty Reminds Investors Launches Need Time
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s sales of Advair nose-dived 15% in the first quarter due to pricing pressure and loss of insurance coverage. New respiratory products like Breo Ellipta have yet to make a dent toward shoring up respiratory sales.
You may also be interested in...
With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
Merck & Co. Remains 'Very Confident' In TIGIT
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.
From Hallelujah To Headwind: Pfizer's COVID-19 Franchise Hits The Downturn
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.